Skip to main content
. 2016 Oct 18;18(12):1000–1009. doi: 10.1016/j.hpb.2016.09.004

Table 2.

Preoperative CEA level according to patients characteristics and time period

CEA, median
2000–2007 (n = 216) P 2008–2015 (n = 268) P
Patient characteristics
 Gender
 Male 7 0.906 7.6 0.488
 Female 7.1 8.4
 Age, years
 > 55 7.3 0.366 7.7 0.335
 ≤ 55 7.0 7.6
Primary tumor characteristics
 Tumor site
 Right 7.4 0.816 7 0.637
 Left 7 7.8
 T stage (n = 441)
 T1 or T2 stage 9.6 0.297 7.6 0.639
 T3 or T4 stage 7 8.8
 Nodal metastases
 Positive 7 0.992 7.5 0.234
 Negative 7.1 8.5
Preoperative factors
 Prior history of chemotherapy
 Yes 7 0.480 7.7 0.562
 No 8.6 7.6
 -Modern cytotoxic regimen
 Yes 5.8 0.009 7.6 0.901
 No 10.5 8.2
 -Biological agent
 Yes 5 0.420 9.0 0.145
 No 7.4 7.1
 CRC at hepatectomy
 Present 14.0 0.202 7.8 0.741
 Resected 7.0 7.6
CRLM characteristics
 No. of CRLM
 >2 6.4 0.840 7.4 0.060
 ≤2 7.5 10.1
 Size of largest CRLM, cm
 >3 11.1 <0.001 12.1 <0.001
 ≤3 5.0 6.8
 Bilateral disease
 Positive 7.1 0.770 7.6 0.522
 Negative 6.3 7.4
 K-ras mutation status (n = 402)
 Wild-type 6.4 0.624 10.5 0.110
 Mutated 7.5 7.0

CEA, carcinoembryonic antigen; CRC, colorectal cancer; CRLM, colorectal liver metastases.

Statistical significant values are indicted in bold italics.